CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
First clinical candidate anticipated in “a year or two,” company tells “The Pink Sheet” DAILY.